Baseline characteristics for the 209 patients included in the present study
| Treatment | UK-500,001 | Placebo | ||
| 0.1 mg b.i.d. | 0.4 mg b.i.d. | 1.0 mg b.i.d. | ||
| Subjects n | 53 | 55 | 48 | 53 |
| Male | 37 (70) | 44 (80) | 33 (69) | 38 (72) |
| Age yrs | 65 (45–80) | 63 (43–78) | 62 (46–79) | 65 (45–78) |
| Mean weight kg | 68.5 | 74.8 | 76.6 | 72.9 |
| Smoking n | ||||
| Smoker | 25 | 14 | 16 | 24 |
| Ex-smoker | 28 | 41 | 32 | 29 |
| FEV1 L | 1.37±0.46 | 1.45±0.47 | 1.53±0.48 | 1.43±0.49 |
| FEV1 % pred | 51.0±14.6 | 49.3±12.3 | 53.9±14.2 | 52.2±14.2 |
| Reversibility % | 16.2±15.0 | 14.1±14.8 | 14.0±14.1 | 13.7±16.4 |
Data are presented as n (%), mean (range) and mean±sd, unless otherwise indicated. FEV1: forced expiratory volume in one second; % pred: % predicted.